The stroke pharmacopeia: Current medical therapies

Pharmacotherapy

Volumn 18, Issue 3 II SUPPL., 1998, Pages

  Wittkowsky, Ann K ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANCROD; ANTICOAGULANT AGENT; DANAPAROID; GLYCOSAMINOGLYCAN; HEPARIN; HEPARINOID; NADROPARIN; PLACEBO; STREPTOKINASE;

BLEEDING; BRAIN HEMATOMA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ACUTE DISEASE; ANTICOAGULANTS; BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 0031804223     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Rothrock JF, Hart RG. Antithrombotic therapy in cerebrovascular disease. Ann Intern Med 1991;115:885-95.
2. Sherman DG, Dyken ML, Gent M, et al. Antithrombotic therapy for cerebrovascular disease: an update. Chest 1995;108(suppl 4):444-56.
3. Barnett HJM, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995;332: 238-48.
4. Sandercock PAG, van den Belt AGM, Lindley RI, Slattery J. Antithrombotic therapy in acute ischemic stroke: an overview of completed randomized trials. J Neurol Neurosurg Psychiatry 1993;56:17-25.
5. Toni D, Fiorelli M, Gentile M, et al. Progressing neurological deficit secondary to acute ischemic stroke. A study on predictability, pathogenesis and prognosis. Arch Neurol 1995;52:670-5.
6. Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: a randomized trial. Stroke 1983;14:668-76.
7. Duke RJ, Bloch RF, Turpie AGG, Trebilcock R, Bayer N. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke: a randomized controlled trial. Ann Intern Med 1986;105:825-8.
8. Kay R, Wong KS, Yu YL, et al. Low molecular weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333:1588-93.
9. Albanese MA, Clarke WR, Adams HP Jr, Woolson RF, and TOAST Investigators. Ensuring reliability of outcome measures in multicenter clinical trials of treatments for acute ischemic stroke: the program developed for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST). Stroke 1994;25: 1746-51.
10. Sherman DG, Barbour P, Levy D, et al. Ancrod for the treatment of acute ischemic brain infarction. Stroke 1994;25:1755-9.
11. The Multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-50.
12. Donnan GA, Davis SM, Chambers BR, et al. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996;276:961-6.
13. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.
14. The National Institute of Neurological Disorders and Stroke t-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
15. Adams HP, Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with ischemic stroke. Circulation 1996;94:1167-74.